Anti-SLAMF7 Recombinant Antibody (Elotuzumab) (CAT#: TAB-743)

Recombinant humanized antibody expressed in CHO binding to human SLAMF7/CD319. Elotuzumab is a humanized monoclonal antibody which is under phase III clinical investigation in relapsed multiple myeloma.

Specific Inquiry Online Inquiry
  • Size:
  • Conjugation:
  • Endotoxin:
  • Purity:
  • Fc Engineering:
  • Tested Data
  • Gene Expression
  • Datasheet
  • MSDS
  • COA
ELISA

Figure 1 Anti-SLAMF7 Recombinant Antibody (TAB-743) in ELISA

Figure 1 Anti-SLAMF7 Recombinant Antibody (TAB-743) in ELISA

ELISA analysis of TAB-743 was performed by coating with SLAMF7 antigen. The HRP-conjugated goat anti-human IgG was used as a secondary antibody.

WB

Figure 2 Anti-SLAMF7 Recombinant Antibody (TAB-743) in WB

Figure 2 Anti-SLAMF7 Recombinant Antibody (TAB-743) in WB

Western blot analysis of TAB-743 was performed with 3 µg onto a 12% Tris-HCl polyacrylamide gel in β-mercaptoethanol-reduced (Lane 1) conditions. Goat Anti-Human IgG HRP secondary antibody at a dilution of 1:8,000 for 75 minutes.


Specifications

  • Immunogen
  • The details of the immunogen for this antibody are not available.
  • Host Species
  • Mouse
  • Derivation
  • Humanized (from mouse)
  • Type
  • IgG1 - kappa
  • Species Reactivity
  • Human
  • Applications
  • Suitable for use in FuncS, IF, Neut, ELISA, FC, IP, IHC and most other immunological methods.
  • CAS
  • 915296-00-3
  • Generic Name
  • elotuzumab
  • UNII
  • 1351PE5UGS
  • MW
  • 145.5 kDa
  • Related Disease
  • Multiple myeloma (MM)

Product Property

  • Purity
  • >95.0%, determined by analysis by RP-HPLC & analysis by SDS-PAGE.
  • Storage
  • Store at -20°C. Avoid multiple freeze/thaw cycles.

Target

  • Alternative Names
  • elotuzumab;915296-00-3;HuLuc63;PDL063;PDL-063;BMS-901608;HuLuc63;SLAMF7;SLAM family member 7;19A;CD319;CRACC;CS1;protein 19A;CD2 subset 1;19A24 protein;membrane protein FOAP-12;CD2-like receptor activating cytotoxic cells;CD2-like receptor-activating cyto

Related Resources

  • Biosimilar Overview
Please refer to Elotuzumab Overview to learn more about the mechanism of action, clinical projects, and approved drugs of Elotuzumab.

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Downloads

Download resources about recombinant antibody development and antibody engineering to boost your research.

See other products for "Elotuzumab"

Afuco™ Anti-SLAMF7 ADCC Recombinant Antibody (Elotuzumab), ADCC Enhanced
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant humanized antibody expressed in CHO binding to human SLAMF7/CD319. Elotuzumab is a humanized monoclonal antibody which is under phase III clinical investigation in relapsed multiple myeloma.

See other products for "SLAMF7"

Humanized Antibody

CAT Product Name Application Type
TAB-570CL Human Anti-SLAMF7 Recombinant Antibody (TAB-570CL) IF, IHC, Inhib Human IgG

ADCC Enhanced Antibody

CAT Product Name Application Type
AFC-TAB-743 Afuco™ Anti-SLAMF7 ADCC Recombinant Antibody (Elotuzumab), ADCC Enhanced FuncS, IF, Neut, ELISA, FC, IP ADCC enhanced antibody

Submit a review or a question
There are currently no Customer reviews or questions for TAB-743. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.

For Research Use Only. Not For Clinical Use.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Send Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

  • 0
  • 0
Cart
    Go to compare

    Go to compare